Central control of bone mass: potential therapeutic implications.
Levasseur
Régis
R
Rheumatology Department and Bone and Joint Center, Angers Teaching Hospital, 4, rue Larrey, 49 933 Angers cedex 9, France. relevasseur@chu-angers.fr
Legrand
Erick
E
Chappard
Daniel
D
Audran
Maurice
M
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects* / Q000502:physiology*; D006801:Humans; D020738:Leptin / Q000627:therapeutic use; D010024:Osteoporosis / Q000188:drug therapy; D011433:Propranolol / Q000494:pharmacology; D011994:Recombinant Proteins / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D020738:Leptin; D011994:Recombinant Proteins; D011433:Propranolol